New patent for Boehringer Ingelheim drug OFEV

Published on May 12, 2023

Annual Drug Patent Expirations for OFEV Ofev is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five patents…

The post New patent for Boehringer Ingelheim drug OFEV appeared first on DrugPatentWatch - Make Better Decisions.

The post New patent for Boehringer Ingelheim drug OFEV appeared first on Biotechblog.

Continue reading on website
Other news

New patent for Xellia Pharms drug VANCOMYCIN HYDROCHLORIDE

May 12, 2023
Annual Drug Patent Expirations for VANCOMYCIN+HYDROCHLORIDE Vancomycin Hydrochloride is a drug marketed by Akorn, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Strides Pharma, Watson Labs, Alkem Labs Ltd,…The post New patent for Xellia Pharms drug VANCOMYCIN HYDROCHLORIDE appeared first on DrugPatentWatch - Make Better Decisions.The post New patent for Xellia Pharms drug VANCOMYCIN HYDROCHL

Life Biosciences and Forge Biologics Sign Gene Therapy Manufacturing Partnership Agreement

May 12, 2023
Life Biosciences and Forge Biologics entered into a manufacturing partnership to help advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications.“Life Bio is an emerging leader in the development of novel therapies for aging-related diseases, and we are thrilled to serve as their cGMP manufacturing par